Clinical Trial Update: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma [Phase 4]

View source ↗

Summary

This document provides an update on a Phase 4 clinical trial evaluating self-administered subcutaneous daratumumab for relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Odense University Hospital | Conditions: Multiple Myeloma in Relapse | Phase 4 | Status: NOT_YET_RECRUITING